Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
How a minnow little company called sareum become an over night hit, by saving the world of Covid-19 and not to mention cancer. Headlines across the world, oh sorry just dreaming.
great info update guys..
watched the video last year, that's when i started topping up on any dips, this was pre Covid 19.. now this is really game on, which big pharma will be the lucky one? Had my knuckles wrapped by Tim in a subtle way day before the Bio Presentation!
If reading Tim, hope you are more than capable (your words.....)
GLALTH's this has got game over written all over it
I also like the 'been rumoured for weeks' been rumours here for weeks!
This is the paragraph from the finals RNS-
Sareum believes SDC-1801 represents a strong candidate entering an area of increasing industry interest with substantial clinical validation. The Company's view has been formed based on the progress of molecules in clinical development by Bristol-Myers Squibb (BMS-986165; TYK2 inhibitor) and Pfizer (PF-06700841; TYK2/JAK1 inhibitor) in psoriasis and other autoimmune diseases, which has been promising but also shown signals that suggest there is an opportunity for a molecule with best-in-class properties.
Furthermore, several licensing deals for preclinical and clinical-stage assets have been completed recently in the sector with highly attractive economic terms, such as:
· TD-1473 (a pan-JAK inhibitor) - licensed by Janssen from Theravance (2018) at the end of Phase 1 studies for $100M cash up-front, up to $900M in milestone payments, plus royalties.
· Filgotinib (JAK1 inhibitor) - licensed by Gilead from Galapagos (2015) at the end of Phase 2 trials for $300M cash and $425M equity investment up-front, up to $1,350M in milestone payments, plus 20%+ royalties.
· Undisclosed TYK2 inhibitor (plus other assets) - Celgene formed an alliance with Nimbus Therapeutics (2017) in preclinical stage for undisclosed up-front and milestone payments.
Approved products targeting the JAK family with blockbuster sales potential, despite warnings based on side effects related to JAK2/JAK3 activity, include: · Xeljanz® tofacitinib (Pfizer) (JAK1/JAK3 inhibitor) - approved for rheumatoid and psoriatic arthritis and ulcerative colitis, with 2017 sales of $1.35Bn, despite black box warnings for serious infections and lymphoma.
· Olumiant® baricitinib (Eli Lilly) (JAK1/JAK2 inhibitor) - approved from rheumatoid arthritis, with expected peak sales of approximately $1Bn, but with black box warnings for serious infections, lymphoma and thrombosis.
Jakafi® ruxolitinib (Incyte/Novartis) - approved for myelofibrosis and polycythemia vera (a type of blood cancer) with 2017 sales of $1.1Bn despite warnings of infections and blood cell counts.
The scale of the deals and sales delivered/forecast for these candidates and products targeting TYK2 and related JAK family members gives Sareum confidence in the exciting, high value market opportunity for SDC-1801.
*Sources include company information and analyst consensus as reported in BioWorld "FDA approves Lilly and Incyte's baricitinib for second-line RA treatment" 4 June 2018
Working, Tim, John and the Nomad have been mulling these types of amounts for some time. That's why they very deliberately put previous tyk and jak licensing deal amounts in the finals RNS in 2018. Make of it what you wish but it would all need approving and signing off before RNS- so they very much believe they can achieve similar amounts and with the covid19 angle now added potentially more- it is beggars belief with a worldwide pandemic and so much emphasis being placed on risperatory immunotherapy and with Sar having the only tyk2 available for licence in the world and at oral application as well that no major is looking at licencing or partnering us up.
Thanks for that...shudda kept it to yourself..just in case nothing comes of the presentation...
Endpoints notes:
'At this point, practically everyone who’s big in oncology has a PD-(L)1 either approved, in the pipeline or partnered. Merck may have a commanding lead on the pack with Keytruda, followed by Bristol Myers’ Opdivo, but the future of cancer R&D revolves closely around checkpoints and combos. Having one helps control pricing for anything else you market with it.'
Did you see the figures for the PD-1 from Gilead?????
$375 million upfront
$400 million for R&D
$1.22 billion in reserve to cover opt-in payments and milestones...
Similar to figures quoted by TM previously for our Tyk2 and comparative deals
There’s big money being thrown around at present, more so now than ever before
https://vimeo.com/329309219
2 mins 25 s in "completely regress tumours in mice models".
I suspect Gilead have their stake in SRRA more for 737 than momo. obvs difference of strategy with NG. see if we get or £8m milestone shortly
Hi thoth. Hope you are feeling better. Looks like this scientist loves our molecule. How much would you say this combo on its own puts to the value to share? This is the only golden egg that sierea have in its portfolio and hopefully the new ceo will realise it. Mono thing is nonsense .....
Things could get very tasty.
The lovely Triparna Sen got her grant through. After the brilliant work she did on SRA737 as a combo with PD-1/ PD--L1 inhibitors.
http://filecache.investorroom.com/mr5ircnw_sierra/213/Sierra_AACR%20Miami%202018_SRA737%20IO_FINAL.pdf
And what has Gilead just bought ? A PD-1 (endpoints seems to think for use in combo therapies)
https://endpts.com/gilead-leases-partner-rights-to-tigit-pd-1-in-a-2b-deal-with-arcus-now-comes-the-hard-part/
could get very very tasty very very quickly :)
Good luck falkirk.
Hope we wont have to wait much longer for a decent bit of news and SP action that will bring the end game into sight.
The purchase of 276177 is mines
Long term holder of Sareum (my first purchase was at 3.46p in February 2011) and reader of the chat but rare poster myself
The strange amount takes my holding to a round 1 million and now my average is 1.25p.
Sadly I never had the funds to buy when down in the 0.3p mark
I don't have much success with my share purchases so hopefully i don't jinx this one
GLALTH